These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34499728)

  • 1. Comparison of in vitro activities of plazomicin and other aminoglycosides against clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    İnce G; Mirza HC; Üsküdar Güçlü A; Gümüş H; Erol Ç; Başustaoğlu A
    J Antimicrob Chemother; 2021 Nov; 76(12):3192-3196. PubMed ID: 34499728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
    Galani I; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Souli M;
    BMC Infect Dis; 2019 Feb; 19(1):167. PubMed ID: 30770727
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Fleischmann WA; Greenwood-Quaintance KE; Patel R
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
    Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
    Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
    Almaghrabi R; Clancy CJ; Doi Y; Hao B; Chen L; Shields RK; Press EG; Iovine NM; Townsend BM; Wagener MM; Kreiswirth B; Nguyen MH
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4443-51. PubMed ID: 24867988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
    Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
    J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
    Zhang Y; Kashikar A; Bush K
    J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Activity of Plazomicin Against Carbapenem Resistant Klebsiella pneumoniae Strains.
    Demirbas Z; Ozger HS; Suzuk-Yildiz S; Bakkaloglu Z; Dizbay M
    Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative
    Mirza HC; Güçlü AÜ; İnce Ceviz G; Başustaoğlu A
    J Med Microbiol; 2022 Oct; 71(10):. PubMed ID: 36301611
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.
    Clark JA; Kulengowski B; Burgess DS
    Diagn Microbiol Infect Dis; 2020 Oct; 98(2):115117. PubMed ID: 32755805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.
    Haidar G; Alkroud A; Cheng S; Churilla TM; Churilla BM; Shields RK; Doi Y; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5208-14. PubMed ID: 27297487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
    J Antimicrob Chemother; 2021 Jul; 76(8):2061-2070. PubMed ID: 34097032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of plazomicin and older aminoglyosides against Enterobacterales isolates; prevalence of aminoglycoside modifying enzymes and 16S rRNA methyltransferases.
    Gür D; Hasdemir U; Çakar A; Çavuşoğlu İ; Çelik T; Aksu B;
    Diagn Microbiol Infect Dis; 2020 Aug; 97(4):115092. PubMed ID: 32569921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
    Walkty A; Adam H; Baxter M; Denisuik A; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2014 May; 58(5):2554-63. PubMed ID: 24550325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
    Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
    J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates.
    Emiliov T; Rodríguez-Avial I; López-Diaz MDC; Culebras E
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114867. PubMed ID: 31402069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Plazomicin Tested against
    Castanheira M; Sader HS; Mendes RE; Jones RN
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.
    Galani I; Souli M; Daikos GL; Chrysouli Z; Poulakou G; Psichogiou M; Panagea T; Argyropoulou A; Stefanou I; Plakias G; Giamarellou H; Petrikkos G
    J Chemother; 2012 Aug; 24(4):191-4. PubMed ID: 23040681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers.
    Sader HS; Mendes RE; Kimbrough JH; Kantro V; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad058. PubMed ID: 36861086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.